Susceptibility of Ugandan Plasmodium falciparum Isolates to the Antimalarial Drug Pipeline
Abstract
Drug resistance necessitates the development of new antimalarial drugs. It is important to assess the activities of compounds under development against parasites now causing disease in Africa, where most malaria cases occur, and to determine if mutations in these parasites may limit the efficacies of new agents.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 15, 2023
- Source ID
- 10.1128/spectrum.05236-22
Entities
People
- Alasdair Smith
- Barbara Forte
- Benjamin Blasco
- David Giesbrecht
- Hiroki Kano
- Jeffrey A. Bailey
- Jennifer Legac
- Martin Okitwi
- Maëlle Duffey
- Melissa D Conrad
- Oriana Kreutzfeld
- Oswald Byaruhanga
- Ozkan Aydemir
- Patrick K. Tumwebaze
- Peter Campbell
- Philip J Rosenthal
- Roland A. Cooper
- Samuel L. Nsobya
- Stephanie A. Rasmussen
- Stephen Orena
- Thomas Katairo
Organizations
- Brown University
- Dominican University of California
- Infectious Diseases Research Collaboration
- Istituto Superiore di Sanità
- Medicines for Malaria Venture
- Mitsubishi Tanabe Pharma
- University of California, San Francisco
- University of Dundee
- University of Massachusetts Medical School